These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 19528367

  • 21. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J.
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
    Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K.
    Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B.
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
    DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS, Saxagliptin 014 Study Group.
    Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
    [Abstract] [Full Text] [Related]

  • 31. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, Oh TK.
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [Abstract] [Full Text] [Related]

  • 32. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S.
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [Abstract] [Full Text] [Related]

  • 33. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW.
    Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
    [Abstract] [Full Text] [Related]

  • 34. Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
    Kuhadiya ND, Ghanim H, Mehta A, Garg M, Khan S, Hejna J, Torre B, Makdissi A, Chaudhuri A, Batra M, Dandona P.
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3506-15. PubMed ID: 27490915
    [Abstract] [Full Text] [Related]

  • 35. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M.
    Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
    [Abstract] [Full Text] [Related]

  • 36. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S.
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [Abstract] [Full Text] [Related]

  • 37. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
    Grandy S, Langkilde AM, Sugg JE, Parikh S, Sjöström CD.
    Int J Clin Pract; 2014 Apr; 68(4):486-94. PubMed ID: 24499168
    [Abstract] [Full Text] [Related]

  • 38. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ.
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [Abstract] [Full Text] [Related]

  • 39. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L.
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [Abstract] [Full Text] [Related]

  • 40. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, Urban McCarthy S, Abdul-Ghani M, DeFronzo RA.
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.